Telocyte
Private Company
Funding information not available
Overview
Telocyte is a private, preclinical-stage biotech targeting a fundamental cure for Alzheimer's disease through telomerase gene therapy. The company, founded by Dr. Michael Fossel, a pioneer in the field, posits that telomere shortening in glial cells triggers the pathological cascade of Alzheimer's, and restoring telomerase activity can reverse this process. While still in the research and development phase, Telocyte plans to initiate human clinical trials to test its hypothesis, positioning itself in the high-risk, high-reward space of disease-modifying Alzheimer's therapies. The company's mission is driven by a personal commitment to move beyond symptomatic treatments to a genuine reversal of the disease.
Technology Platform
Telomerase gene therapy platform targeting cellular aging as the root cause of age-related diseases, starting with Alzheimer's. Aims to reset telomere length and senescent gene expression in glial cells.
Opportunities
Risk Factors
Competitive Landscape
Telocyte operates in the highly competitive Alzheimer's space but with a unique mechanism. It competes indirectly with large pharma companies developing amyloid (Eisai/Biogen's Leqembi), tau, and anti-inflammatory therapies. Its direct competitors are other companies targeting cellular senescence or aging (e.g., Unity Biotechnology, Life Biosciences), though few are applying telomerase gene therapy directly to the CNS.